NTS 071
Alternative Names: NTS-071Latest Information Update: 03 Jul 2026
At a glance
- Originator NUTSHELL Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Tumour suppressor protein p53 stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 04 Aug 2025 Phase-I/II clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (PO) (NCT07060989)
- 04 Aug 2025 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in USA (PO) (NUTSHELL Therapeutics pipeline, November 2025) (NCT07060989)
- 04 May 2025 Nutshell Therapeutics plans a phase I trial for Solid tumours (Late-stage disease) in the USA and China (PO) (NCT07060989)